Cost-effective prescribing in chronic obstructive pulmonary disease

Autor:	Steven Hickey
Rok vydání:	2013
Předmět:	medicine.medical_specialty COPD business.industry Pulmonary disease Pharmacology (nursing) Audit Airflow obstruction medicine.disease respiratory tract diseases Inspiratory flow medicine In patient Salmeterol Intensive care medicine business Fluticasone medicine.drug
Zdroj:	Nurse Prescribing. 11:460-462
ISSN:	2052-2924 1479-9189
DOI:	10.12968/npre.2013.11.9.460
Popis:	This article highlights the cost implications when prescribing the different delivery devices available for salmeterol/fluticasone (Seretide, Allen & Hanburys) in patients with chronic obstructive pulmonary disease (COPD). The prescribing licence for combination inhalers in COPD is specific to both drug dosing and delivery device. The perception amongst some practitioners is that patients with moderate to severe airflow obstruction (FEV1
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::34878d48266140a69cb54f369619f9f1 https://doi.org/10.12968/npre.2013.11.9.460 Zobrazit plný text záznamu